Summary:
A Phase 3 study to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus (RSV) prefusion F subunit vaccine in adults older that 60.
Qualified Participants Must:
• Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures
• Healthy participants 60 years and older
• Be capable of giving signed informed consent
Qualified Participants May Receive:
Health Checks, Assessments & Physical Examination in relation to study no cost to you. Access to study drug while in study and compensation of $3,125 for qualifying participants.